Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that ...

VHH antibodies, they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But ...

The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...